Why do patients with obesity discontinue glucagon-like peptide 1 analogues?
-
Almohaileb FI, le Roux CW, Crotty M.
Why do patients with obesity discontinue glucagon-like peptide 1 analogues? Diabetes Obes Metab
Publication Category: Medications
GLP-1 receptor agonists for the treatment of obesity in children and adolescents: a meta-analysis of randomized controlled trials
- Romariz LM, de Melo AAC, Finnegan E, Mesquita Y, Janovsky CCPS. GLP-1 receptor agonists for the treatment of obesity in children and adolescents: a meta-analysis of randomized controlled trials Pediatr Res
Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide
-
Linetzky B, Sattar N, Verma S, Krumholz HM, Xie CC, Hoffmann HT, Zimner-Rapuch S, Torcello-Gómez A, Stefanski A.
Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide Ann Intern Med
Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis
-
Pan XH, Tan B, Chin YH, Lee ECZ, Kong G, Chong B, Kueh M, Khoo CM, Mehta A, Majety P, Grandhi GR, Dimitriadis GK, Foo R, Chew NWS, Le Roux CW, Mamas MA, Chan MY.
Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis Obesity (Silver Spring)
Obesity and its management in primary care setting
-
Ibrahim M, Ba-Essa EM, Alvarez JA, Baker J, Bruni V, Cahn A, Ceriello A, Cosentino F, Davies MJ, De Domenico F, Eckel RH, Friedman AN, Goldney J, Hamtzany O, Isaacs S, Karadeniz S, Leslie RD, Lingvay I, McLaughlin S, Mobarak O, Del Prato S, Prattichizzo F
Obesity and its management in primary care setting Journal of Diabetes and its complications
Glucagon-like peptide 1 (GLP-1) receptor agonists’ use during pregnancy: Safety data from regulatory clinical trials
-
Parker CH, Slattery C, Brennan DJ, le Roux CW.
Glucagon-like peptide 1 (GLP-1) receptor agonists’ use during pregnancy: Safety data from regulatory clinical trials Diabetes, Obesity & Metabolism
Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review
-
Al Lawati A, Alhabsi A, Rahul R, Savino ML, Alwahaibi H, Das S, Al Lawati H.
Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review Diseases (Basel, Switzerland)
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
-
Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP; SURMOUNT-5 Trial Investigators.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity The New England Journal of Medicine
Global barriers to decision makers for prioritizing interventions for obesity
-
Ehlers LH, Reinstrup NW, Olesen RH, Holm JC, McEwan P, Le Roux CW.
Global barriers to decision makers for prioritizing interventions for obesity International Journal of Obesity
A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland
-
Barrett R, Smith A, Gorry C, Doran S, Barry M, McCullagh L.
A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland The Journal of the International Society for Pharmaeconomics and Outcomes Research